Selenite (Sodium) / p65 Cancer Research Results

SSE, Selenite (Sodium): Click to Expand ⟱
Features:
Sodium Selenite - is inorganic selenium in the selenite oxidation state (Se⁴⁺)
Sodium selenite is produced industrially from selenium metal, which itself is obtained as a by-product of copper refining.
Mechanistic distinction from Selenium:
-Selenite reacts with GSH → GS–Se–SG intermediates
-Generates superoxide, H₂O₂
-Exploits cancer cells’ elevated basal oxidative stress
-Normal cells neutralize it more effectively (higher redox reserve)

Both the uptake and processing of selenium has recently shown to be upregulated in subsets of cancer cells
 due to their increased expression of xCT transporter
The more a tumor depends on xCT, the more toxic selenite becomes. High xCT Also Increases SSE Toxicity. High xCT increases intracellular thiols, which increases SSE chemical trapping, redox cycling, and cytotoxic impact.

Sodium selenite might protect against toxicity of AgNPs. also here


SSE and cancer
Rank Pathway / Target Axis Direction Primary Effect Notes / Cancer Relevance Ref
1 Redox cycling with thiols (superoxide generation) ↑ O2•− / ↑ ROS Acute oxidative stress Defines sodium selenite anticancer mechanism in many models: early superoxide rise precedes mitochondrial apoptotic events (ref)
2 Glutathione buffering (GSH pool) ↓ GSH Loss of redox buffering Work in hepatoma models demonstrates GSH’s key role in selenite-driven oxidative stress and apoptosis (ref)
3 Mitochondrial integrity (ΔΨm) ↓ ΔΨm Mitochondrial dysfunction Sequential mechanism shown: superoxide rise → mitochondrial depolarization (ref)
4 Intrinsic apoptosis (cytochrome c → Caspase-9/3) ↑ cytochrome c release / ↑ Caspase-9/3 Programmed cell death Same sequential model shows cytochrome c release followed by caspase-9 and caspase-3 activation (ref)
5 ER stress / UPR (PERK → eIF2α → ATF4) ↑ PERK/eIF2α/ATF4 Proteotoxic stress signaling ER-stress module is shown as a core driver in selenite-induced autophagy→apoptosis progression (ref)
6 Stress MAPK (p38) as switch control ↑ p38 activation Signal switching (autophagy → apoptosis) Mechanistic evidence for p38 participating in the selenite-driven transition toward apoptosis (ref)
7 p53 activation (stress response) ↑ p53 phosphorylation (Ser15) Facilitates apoptosis programs NB4 leukemia model: selenite induces p53 Ser15 phosphorylation via p38/ERK in the autophagy–apoptosis switch context (ref)
8 DNA damage response (ATM-dependent signaling) ↑ ATM-dependent DDR Checkpoint activation & death signaling Selenium compounds (including selenite contexts) activate ATM-dependent DNA damage response signaling in colorectal cancer models (ref)
9 PI3K–AKT axis linked to autophagy/apoptosis balance ↓ PI3K/Akt (functional axis) / ↓ protective autophagy Apoptosis sensitization NB4 leukemia: sodium selenite increases apoptosis by autophagy inhibition through PI3K/Akt (ref)
10 NF-κB signaling ↓ NF-κB Reduced anti-apoptotic transcription Mechanistic study: sodium selenite induces ROS-mediated inhibition of NF-κB with downstream shift toward apoptosis (ref)
11 Angiogenesis signaling (VEGF) ↓ VEGF expression Reduced vascular support signals Prostate cancer PC3 model: sodium selenite inhibits expression of VEGF (and related inflammatory/pro-growth factors) in the tested context (ref)
12 Ferroptosis (iron-dependent oxidative death) ↑ ferroptosis Non-apoptotic oxidative death modality Paper explicitly reports sodium selenite as an inducer of ferroptosis across multiple human cancer cell types (ref)

Table to compare Sodium Selenite to SeNPs
-Sodium selenite → chemical oxidant (thiol attack → ROS shock).
-SeNPs → engineered redox stressor (signaling-level control, broader window).
-Selenomethionine / Se-yeast → redox buffer & selenium storage form (often protective to cancer cells, especially when oxidative stress is a therapeutic goal).
Dimension Sodium Selenite (Na2SeO3) Selenium Nanoparticles (SeNPs) Selenomethionine / Se-Yeast
Primary mechanistic class Direct redox-disrupting agent Controlled redox modulator / signaling perturbator Nutritional selenium reservoir / selenoprotein precursor
Initial molecular interaction Rapid reaction with cellular thiols (GSH, Trx, protein –SH) Cellular uptake → gradual selenium release or surface redox effects Nonspecific incorporation into proteins in place of methionine
ROS generation ↑↑ acute, non-buffered ROS burst ↑ mild–moderate, sustained ROS ↓ or ↔ (antioxidant bias)
Glutathione (GSH) system ↓↓ GSH depletion ↔ or mild ↓ (context-dependent) ↑ GSH recycling via GPX support
Redox selectivity (cancer vs normal) Limited; toxicity threshold close to efficacy Improved tumor selectivity window Poor for cancer killing; favors normal-cell protection
Mitochondrial integrity (ΔΨm) ↓↓ rapid depolarization ↓ gradual, dose-dependent disruption ↔ or ↑ mitochondrial protection
Dominant cell-death pathways Intrinsic apoptosis ± necrosis (high dose) Apoptosis ± ferroptosis ± autophagy-related death None (cytoprotective)
ER stress / UPR (PERK–CHOP) ↑ strong, early activation ↑ moderate, delayed activation ↓ ER stress via antioxidant capacity
DNA damage response ↑ oxidative DNA lesions (ATM/ATR) ↑ low–moderate, secondary to ROS ↓ DNA damage; improved repair environment
PI3K–AKT survival signaling ↓ secondary to oxidative collapse ↓ reported in multiple tumor models ↔ or ↑ survival signaling
NF-κB / inflammatory signaling ↓ via redox inhibition ↓ selectively; anti-inflammatory bias ↓ chronic inflammation (protective)
Ferroptosis involvement Minor / indirect ↑ lipid peroxidation; GPX4 modulation ↓↓ ferroptosis risk (GPX4 support)
Autophagy ↑ early (protective) → collapse ↑ contributory to tumor suppression ↔ homeostatic maintenance
Angiogenesis (VEGF) ↓ at cytotoxic doses ↓ at lower, tolerated doses ↔ or mild ↓ (indirect)
Immune compatibility Poor at anticancer doses Moderate–good; often immune-supportive High; supports immune competence
Pharmacologic control Poor (steep dose–toxicity curve) High (size, coating, release tunable) Low (slow turnover, storage form)
Normal tissue tolerance Low Moderate–high High
Overall cancer relevance Potent but hazardous cytotoxic agent Balanced anticancer redox modulator Generally counterproductive for direct cancer killing
Overall therapeutic profile Potent but narrow safety margin Lower acute potency, broader usable window


p65, RelA: Click to Expand ⟱
Source:
Type:
P65, also known as RelA, is a subunit of the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) transcription factor complex. NF-κB plays a crucial role in regulating immune response, inflammation, and cell survival.
Due to its role in cancer progression, p65 and the NF-κB pathway are considered potential therapeutic targets. Inhibitors of NF-κB signaling are being explored in preclinical and clinical studies as potential cancer treatments.
Many studies have reported that p65 is overexpressed in various types of cancers, including breast, prostate, lung, and colorectal cancers.
In some cancers, elevated p65 levels correlate with higher grades of tumors and advanced stages of disease.

"RELA proto-oncogene, NF-κB subunit." It encodes the p65 protein, which is a central component of the NF‑κB transcription factor complex.
-Chronic activation of RELA and the NF‑κB pathway is frequently associated with cancer progression, promoting inflammation-driven tumorigenesis, chemoresistance, and metastasis.
-RELA interacts with other oncogenic signaling networks (for example, STAT3 and MAPK pathways), further integrating environmental signals that favor cancer progression.

RELA (p65) is a critical subunit of the NF‑κB transcription factor complex, involved in the regulation of genes that control inflammation, cell survival, and proliferation. In the context of cancer, aberrant activation and overexpression of RELA are frequently associated with aggressive tumor behavior, therapy resistance, and poorer patient outcomes in cancers such as breast, lung, colorectal, and pancreatic cancers, among others.

RELA emerges as a potential key contributor to the suppression of glycolysis, mitochondrial respiration, and ATP production in cancer cells. (RELA knockdown signifcantly reduced the tumorigenic.
potential of various pancreatic cancer cell lines).


Scientific Papers found: Click to Expand⟱
5112- SSE,    https://pubmed.ncbi.nlm.nih.gov/19811770/
- in-vitro, Pca, PC3
VEGF↓, IL6↓, NF-kB↓, p65↓,
5111- SSE,    Sodium selenite induces apoptosis via ROS-mediated NF-κB signaling and activation of the Bax-caspase-9-caspase-3 axis in 4T1 cells
- in-vitro, BC, 4T1
ROS↑, NF-kB↓, p65↓, mtDam↑, Casp9↑, Casp3↑, Apoptosis↑, eff↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

ROS↑, 1,  

Mitochondria & Bioenergetics

mtDam↑, 1,  

Cell Death

Apoptosis↑, 1,   Casp3↑, 1,   Casp9↑, 1,  

Angiogenesis & Vasculature

VEGF↓, 1,  

Immune & Inflammatory Signaling

IL6↓, 1,   NF-kB↓, 2,   p65↓, 2,  

Drug Metabolism & Resistance

eff↓, 1,  

Clinical Biomarkers

IL6↓, 1,  
Total Targets: 11

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: p65, RelA
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:148  Target#:238  State#:%  Dir#:1
wNotes=0 sortOrder:rid,rpid

 

Home Page